Related Experiment Videos

Biorecognition of antibodies in vivo: potential in drug targeting

A R Fritzberg¹

¹NeoRx Corporation, Seattle, WA 98119, USA.

Journal of Molecular Recognition : JMR

|September 1, 1996

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity.

Proceedings of the National Academy of Sciences of the United States of America·2000

Simplified preformed chelate protein radiolabeling with technetium-99m mercaptoacetamidoadipoylglycylglycine (N3S-adipate).

Bioconjugate chemistry·1998

The development of technetium-99m-labelled interleukin-2: a new radiopharmaceutical for the in vivo detection of mononuclear cell infiltrates in immune-mediated diseases.

Nuclear medicine and biology·1997

186Re-labeled antibodies to p185HER2 as HER2-targeted radioimmunopharmaceutical agents: comparison of physical and biological characteristics with 125I and 131I-labeled counterparts.

Cancer biotherapy & radiopharmaceuticals·1996

Rhenium-186-labeled chimeric antibody NR-LU-13: pharmacokinetics, biodistribution and immunogenicity relative to murine analog NR-LU-10.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·1993

Tumor cell retention of antibody Fab fragments is enhanced by an attached HIV TAT protein-derived peptide.

Biochemical and biophysical research communications·1993

See all related articles